当前位置:
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-11-18 , DOI: 10.1016/s1470-2045(24)00596-5 Robin Forrest MSc, Mylene Lagarde PhD, Prof Ajay Aggarwal MD PhD, Huseyin Naci PhD
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-11-18 , DOI: 10.1016/s1470-2045(24)00596-5 Robin Forrest MSc, Mylene Lagarde PhD, Prof Ajay Aggarwal MD PhD, Huseyin Naci PhD
The extent to which patients with cancer are willing to accept uncertainty about the clinical benefit of new cancer drugs in exchange for faster access is not known. This study aims to examine preferences for access versus certainty, and to understand factors that influence these preferences.
中文翻译:
对新癌症药物的获取速度与生存获益确定性的偏好:一项离散选择实验
癌症患者在多大程度上愿意接受新癌症药物临床益处的不确定性以换取更快的可及性尚不清楚。本研究旨在检查对访问的偏好与确定性,并了解影响这些偏好的因素。
更新日期:2024-11-18
中文翻译:
对新癌症药物的获取速度与生存获益确定性的偏好:一项离散选择实验
癌症患者在多大程度上愿意接受新癌症药物临床益处的不确定性以换取更快的可及性尚不清楚。本研究旨在检查对访问的偏好与确定性,并了解影响这些偏好的因素。